Form 8-K TG THERAPEUTICS, INC. For: Mar 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cantor Fitzgerald Reiterates Overweight Rating on TG Therapeutics (TGTX)
March 3, 2025 1:07 PM ESTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).
The analyst comments "TGTX stock is up >18% (XBI: -1%) on the back of positive comments on the 4Q call around 1Q trends for Briumvi (anti-CD20 drug in... More
